Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EUGENE BLANCHARD CONE

Allopathic & Osteopathic Physicians Urology

NPI
1083955538
CMS profile
6368399
Location
GREENWOOD, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$44,715.63

83 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EUGENE BLANCHARD CONE

NPI 1083955538 · CMS profile ID 6368399

Allopathic & Osteopathic Physicians / Urology

GREENWOOD, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EUGENE BLANCHARD CONE, NPI 1083955538, CMS profile ID 6368399. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EUGENE BLANCHARD CONE, NPI 1083955538, CMS profile ID 6368399. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EUGENE BLANCHARD CONE, NPI 1083955538, CMS profile ID 6368399, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1083955538?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

83 matching records · $44,715.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 83 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–83 of 83.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $12.5707/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139298726 CMS
Merck Sharp & Dohme LLC $18.5306/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141726041 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.3306/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152148770 CMS
Janssen Biotech, Inc. $125.6805/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078619866 CMS
Janssen Biotech, Inc. $32.2505/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078620277 CMS
IMMUNITYBIO, INC. $176.7105/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125508362 CMS
ABBVIE INC. $19.1105/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103495624 CMS
Astellas Pharma US Inc $130.7705/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139371433 CMS
Ferring Pharmaceuticals Inc. $51.8605/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137470698 CMS
Janssen Biotech, Inc. $147.4705/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078620241 CMS
Janssen Biotech, Inc. $17.3105/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078620339 CMS
Dendreon Pharmaceuticals LLC $49.5405/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149314348 CMS
Dendreon Pharmaceuticals LLC $30.4104/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149314346 CMS
Merck Sharp & Dohme LLC $137.4004/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141726043 CMS
Dendreon Pharmaceuticals LLC $25.4603/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149314344 CMS
Dendreon Pharmaceuticals LLC $123.1103/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149314342 CMS
PROCEPT BioRobotics Corporation $58.9702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144030132 CMS
PROGENICS PHARMACEUTICALS, INC. $20.4502/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128514823 CMS
Janssen Biotech, Inc. $18.1802/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078620004 CMS
PFIZER INC. $21.5602/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131631634 CMS
Agiliti Surgical, Inc. $31.3401/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153264309 CMS
Agiliti Surgical, Inc. $48.0601/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153264397 CMS
UROGEN PHARMA, INC. $20.4501/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137922717 CMS
Dendreon Pharmaceuticals LLC $27.3801/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149314340 CMS
Ferring Pharmaceuticals Inc. $48.2101/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137470692 CMS
Janssen Scientific Affairs, LLC $41.3601/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078850317 CMS
ACCORD HEALTHCARE, INC. $89.6801/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120076472 CMS
Dendreon Pharmaceuticals LLC $73.8801/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149314338 CMS
Janssen Biotech, Inc. $101.6801/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078619935 CMS
Dendreon Pharmaceuticals LLC $157.5801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149314336 CMS
Astellas Pharma US Inc $15.5701/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139308082 CMS
Merck Sharp & Dohme LLC $100.0001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141726045 CMS
Telix Pharmaceuticals $19.9701/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081982278 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $2,702.57 27
PY2023 $10,302.79 48
PY2024 $44,715.63 83
PY2025 $56,543.68 89

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $765,866.83 95
PY2024 Principal investigator $1,040,194.20 98
PY2023 Principal investigator $169,181.80 28
PY2022 Principal investigator $17,121.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

95 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $9,519.00 12/26/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356660
Principal investigator 1 Sumitomo Pharma America, Inc. $1,962.00 12/22/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657724
Principal investigator 1 Janssen Research & Development, LLC $1,570.00 12/16/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216553
Principal investigator 1 Janssen Research & Development, LLC $1,900.00 12/15/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357075
Principal investigator 1 Janssen Research & Development, LLC $5,988.00 12/15/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357161
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 12/15/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357252
Principal investigator 1 Janssen Research & Development, LLC $275.00 12/09/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216583
Principal investigator 1 Janssen Research & Development, LLC $3,077.84 12/09/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216648
Principal investigator 1 Janssen Research & Development, LLC $316.00 12/09/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216679
Principal investigator 1 Janssen Research & Development, LLC $16,446.00 11/27/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356605
Principal investigator 1 Janssen Research & Development, LLC $32,575.00 11/27/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356652
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/27/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356692
Principal investigator 1 Janssen Research & Development, LLC $550.00 11/27/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356718
Principal investigator 1 Janssen Research & Development, LLC $1,322.00 11/27/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356897
Principal investigator 1 Janssen Research & Development, LLC $32,892.00 11/27/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356954
Principal investigator 1 Janssen Research & Development, LLC $13,714.00 11/24/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216640
Principal investigator 1 Janssen Research & Development, LLC $275.00 11/24/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357211
Principal investigator 1 Janssen Research & Development, LLC $5,988.00 11/24/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357229
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $4,000.00 11/24/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA, LLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230376
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 11/21/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356554
Principal investigator 1 Janssen Research & Development, LLC $550.00 11/21/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356977
Principal investigator 1 Janssen Research & Development, LLC $275.00 11/13/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216516
Principal investigator 1 Janssen Research & Development, LLC $225.00 11/12/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216530
Principal investigator 1 Janssen Research & Development, LLC $2,944.00 11/12/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216730
Principal investigator 1 Janssen Research & Development, LLC $1,570.00 11/07/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216545
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 11/07/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356811
Principal investigator 1 Janssen Research & Development, LLC $200.00 10/30/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357186
Principal investigator 1 Janssen Research & Development, LLC $13,000.00 10/27/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357177
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $2,865.00 10/21/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA, LLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230340
Principal investigator 1 Janssen Research & Development, LLC $3,077.84 10/16/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216591
Principal investigator 1 Janssen Research & Development, LLC $316.00 10/15/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216615
Principal investigator 1 Janssen Research & Development, LLC $225.00 10/14/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216538
Principal investigator 1 Janssen Research & Development, LLC $2,944.00 10/14/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216705
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/14/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216737
Principal investigator 1 Janssen Research & Development, LLC $36,000.00 10/09/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357007
Principal investigator 1 Janssen Research & Development, LLC $25,384.00 10/06/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356668
Principal investigator 1 Janssen Research & Development, LLC $4,088.00 10/02/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216603
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $1,450.00 09/29/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA, LLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230322
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $3,000.00 09/29/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA, LLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230328
Principal investigator 1 PROGENICS PHARMACEUTICALS, INC. $15,000.00 09/29/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA, LLC
PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR No dispute reported 06/30/2026 1245230332
Principal investigator 1 Janssen Research & Development, LLC $11,183.00 09/22/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356748
Principal investigator 1 Janssen Research & Development, LLC $8,223.00 09/22/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356993
Principal investigator 1 Janssen Research & Development, LLC $474.00 09/17/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216508
Principal investigator 1 Janssen Research & Development, LLC $142.00 09/17/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216561
Principal investigator 1 Janssen Research & Development, LLC $3,393.84 09/17/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216721
Principal investigator 1 Janssen Research & Development, LLC $16,444.00 08/28/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216596
Principal investigator 1 Janssen Research & Development, LLC $273.00 08/18/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216568
Principal investigator 1 Janssen Research & Development, LLC $11,976.00 08/14/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357131
Principal investigator 1 Janssen Research & Development, LLC $138.00 08/04/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175356598
Principal investigator 1 Janssen Research & Development, LLC $1,900.00 07/30/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357242
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 07/28/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356685
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/17/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356583
Principal investigator 1 Janssen Research & Development, LLC $16,446.00 07/17/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356873
Principal investigator 1 Janssen Research & Development, LLC $250.00 07/17/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356965
Principal investigator 1 Janssen Research & Development, LLC $1,570.00 07/14/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216696
Principal investigator 1 Janssen Research & Development, LLC $12,692.00 07/07/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356819
Principal investigator 1 Janssen Research & Development, LLC $3,800.00 06/23/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357031
Principal investigator 1 Janssen Research & Development, LLC $8,954.00 06/13/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216160
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 06/09/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356562
Principal investigator 1 Janssen Research & Development, LLC $17,768.00 06/09/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356763
Principal investigator 1 Janssen Research & Development, LLC $17,768.00 06/09/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356905
Principal investigator 1 Janssen Research & Development, LLC $6,338.00 06/02/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216576
Principal investigator 1 Janssen Research & Development, LLC $20,600.00 05/23/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175357203
Principal investigator 1 Janssen Research & Development, LLC $173.00 05/22/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356570
Principal investigator 1 Janssen Research & Development, LLC $26,652.00 05/22/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356757
Principal investigator 1 Janssen Research & Development, LLC $2,644.00 05/22/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356854
Principal investigator 1 Janssen Research & Development, LLC $44,420.00 05/19/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356888
Principal investigator 1 Janssen Research & Development, LLC $275.00 05/09/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216169
Principal investigator 1 Janssen Research & Development, LLC $474.00 05/09/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216210
Principal investigator 1 Janssen Research & Development, LLC $275.00 05/09/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216663
Principal investigator 1 Janssen Research & Development, LLC $3,393.84 05/09/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216670
Principal investigator 1 Janssen Research & Development, LLC $4,192.00 04/28/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216197
Principal investigator 1 Janssen Research & Development, LLC $1,584.00 04/28/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216623
Principal investigator 1 Janssen Research & Development, LLC $12,692.00 04/28/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356913
Principal investigator 1 Janssen Research & Development, LLC $12,767.00 04/03/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356879
Principal investigator 1 Janssen Research & Development, LLC $6,818.00 03/17/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216174
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 03/07/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216182
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 03/07/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216190
Principal investigator 1 Janssen Research & Development, LLC $6,346.00 03/07/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356970
Principal investigator 1 Janssen Research & Development, LLC $11,722.00 02/21/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216147
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/21/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216631
Principal investigator 1 Janssen Research & Development, LLC $450.00 02/21/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216655
Principal investigator 1 Janssen Research & Development, LLC $6,800.00 02/21/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216689
Principal investigator 1 Janssen Research & Development, LLC $275.00 02/17/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356614
Principal investigator 1 Janssen Research & Development, LLC $16,619.00 02/17/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356635
Principal investigator 1 Janssen Research & Development, LLC $16,446.00 02/17/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356786
Principal investigator 1 Janssen Research & Development, LLC $8,884.00 02/17/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356803
Principal investigator 1 Janssen Research & Development, LLC $1,555.00 02/13/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216525
Principal investigator 1 Janssen Research & Development, LLC $7,461.00 02/10/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356643
Principal investigator 1 Janssen Research & Development, LLC $1,537.00 02/03/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175356621
Principal investigator 1 Janssen Research & Development, LLC $275.00 01/30/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216610
Principal investigator 1 AstraZeneca Pharmaceuticals LP $129,443.87 01/29/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185545057
Principal investigator 1 Sumitomo Pharma America, Inc. $606.60 01/29/2025 Non-covered Recipient Entity
UROLOGY OF INDIANA LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176624963
Principal investigator 1 Janssen Research & Development, LLC $2,096.00 01/28/2025 Non-covered Recipient Entity
Uro Of Indiana Admin Ofc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175216153
Principal investigator 1 Janssen Research & Development, LLC $1,555.00 01/14/2025 Non-covered Recipient Entity
Uro Of Indiana Llc Distr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175216712

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $10,480.00 1
PY2025 Value of interest $15,600.00 1
PY2024 Amount invested $10,480.00 1
PY2024 Value of interest $10,480.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2024–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Central Indiana URS Consumables, LLC $10,480.00 $15,600.00 LLC Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1188127773
PY2024 Central Indiana URS Consumables, LLC $10,480.00 $10,480.00 LLC Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1123484358